减低强度异基因干细胞移植治疗化疗难治性滤泡性淋巴瘤与治疗相关骨髓增生异常综合征并存的情况。
Reduced-intensity allogeneic stem cell transplantation for co-emergence of chemotherapy-refractory follicular lymphoma and therapy-related myelodysplastic syndrome.
作者信息
Shimura Yuji, Kuroda Junya, Sasaki Nana, Uchiyama Hitoji, Ohshiro Muneo, Matsumura Yayoi, Nagoshi Hisao, Mizutani Shinsuke, Kobayashi Tsutomu, Matsumoto Yosuke, Horiike Shigeo, Taniwaki Masafumi
机构信息
Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan ; Division of Hematology, Department of Medicine, Kyoto Second Red Cross Hospital, Kyoto, Japan.
出版信息
Case Rep Oncol. 2014 Mar 13;7(1):188-94. doi: 10.1159/000360905. eCollection 2014 Jan.
A 54-year-old male was diagnosed with follicular lymphoma in September 2003. Despite multiple chemotherapies, including autologous hematopoietic stem cell transplantation (HSCT) with high-dose chemotherapy, the disease eventually relapsed. Additionally, bone marrow analysis revealed the co-emergence of therapy-related myelodysplastic syndrome (t-MDS) in February 2012. In March 2012, we performed related allogeneic HSCT for the treatment of both malignancies. This strategy was successful and the patient has remained free from both malignancies for 23 months. Allogeneic HSCT is a potent curative therapeutic option for both t-MDS and refractory follicular lymphoma.
一名54岁男性于2003年9月被诊断为滤泡性淋巴瘤。尽管接受了包括大剂量化疗的自体造血干细胞移植（HSCT）在内的多种化疗，但疾病最终复发。此外，2012年2月骨髓分析显示出现了治疗相关的骨髓增生异常综合征（t-MDS）。2012年3月，我们进行了相关的异基因HSCT以治疗这两种恶性肿瘤。该策略取得成功，患者已无这两种恶性肿瘤达23个月。异基因HSCT是治疗t-MDS和难治性滤泡性淋巴瘤的一种有效的根治性治疗选择。
Zotero 插件